ArticleScientific reports2026
Prevalence and its associated factors of cancer-related fatigue among liver cancer patients: a cross-sectional study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to identify the prevalence of CRF and its associated factors in liver cancer patients. A cross-sectional study was conducted at a major teaching hospital in Sichuan Province, China, between October and December 2025. A total of 315 liver cancer patients were recruited to complete a survey comprising the demographic and clinical information form, the Cancer Fatigue Scale (CFS), the FRAIL Scale, the Hospital Anxiety and Depression Scale (HADS), and the Pittsburgh Sleep Quality Index (PSQI). Univariate analysis, Least Absolute Shrinkage and Selection Operator (LASSO) regression, and binary logistic regression were employed to determine the factors associated with CRF. Among 315 liver cancer patients, 206 (65.4%) participants were diagnosed with CRF. BCLC stage (A: OR = 2.050, 95% CI: 0.889-4.727, P = 0.092; B: OR = 2.921, 95% CI: 1.260-6.772, P = 0.012; C: OR = 5.247, 95% CI: 2.094-13.150, P < 0.001; D: OR = 7.334, 95% CI: 1.300-41.389, P = 0.024), chemotherapy history (OR = 2.202, 95% CI: 1.153-4.197, P = 0.017), physical frailty (OR = 3.343, 95% CI: 1.880-5.946, P < 0.001), depression (OR = 1.133, 95% CI: 1.063-1.208, P < 0.001), and the PSQI score (OR = 1.278, 95% CI: 1.172-1.394, P < 0.001) were identified as significantly associated factors of CRF in liver cancer patients in the binary logistic regression analysis. CRF was highly prevalent among liver cancer patients and was significantly associated with BCLC stage, chemotherapy history, physical frailty, depression, and PSQI score. Healthcare professionals should consider these critical factors when assessing and managing CRF in liver cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.